AD					

Award Number: DAMD17-03-1-0448

TITLE: Epigenetic Silencing and Resistance to Imatinib Mesylate in CML

PRINCIPAL INVESTIGATOR: Jean-Pierre Issa, M.D.

CONTRACTING ORGANIZATION: University of Texas M.D. Anderson Cancer Center

Houston, TX 77030

REPORT DATE: July 2007

TYPE OF REPORT: Addendum to Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

R	EPORT DOC		Form Approved OMB No. 0704-0188				
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.							
1. REPORT DATE (DD	D-MM-YYYY)	2. REPORT TYPE			ATES COVERED (From - To)		
01-07-2007  4. TITLE AND SUBTIT		Addendum to Final			JUL 2006 - 31 JUN 2007 CONTRACT NUMBER		
				l Gai	30111111101 11311112 <u>1</u> 1		
Epigenetic Silencir	ng and Resistance	to Imatinib Mesylate	e in CML		GRANT NUMBER MD17-03-1-0448		
				5c.	PROGRAM ELEMENT NUMBER		
6. AUTHOR(S)	4.5			5d.	PROJECT NUMBER		
Jean-Pierre Issa, N	и.D.			5e.	TASK NUMBER		
E-Mail: jpissa@m	danderson.org			5f. \	WORK UNIT NUMBER		
7. PERFORMING ORG	ANIZATION NAME(S)	AND ADDRESS(ES)		8. F	ERFORMING ORGANIZATION REPORT		
				ı	IUMBER		
University of Texas Houston, TX 7703		ancer Center					
Tiouston, 17 7703	U						
		IAME(S) AND ADDRES	S(ES)	10.	SPONSOR/MONITOR'S ACRONYM(S)		
U.S. Army Medica Fort Detrick, Maryl		teriei Command					
TOR Detrick, Mary	and 21702-3012			11.	SPONSOR/MONITOR'S REPORT		
					NUMBER(S)		
12. DISTRIBUTION / A	_						
Approved for Publi	C Release, Distribu	ition Onlinited					
13. SUPPLEMENTARY	NOTES						
14. ABSTRACT							
	analyses of DNA	Methylation da	ta reported in the	final report	with clinical outcome of CML		
•	•	•	•	•			
patients. DNA methylation significantly correlated with survival. CML patients with average methylation z-score values above zero had significantly shorter survival than patients with z-scores below zero (median							
10 months vs 59 months, P<0.0001). This was true also within CP (median survival of 44 months for							
,							
patients with high methylation vs median not reached in patients with low methylation, P=0.02) and AP							
(median survival of 11 months for patients with high methylation vs 27 months in patients with low							
methylation, P=0.009). Changes in gene silencing by DNA methylation may play a role in developing alternative routes for cells to circumvent the effects of imatinib.							
alternative route	es for cells to cil	cumvent the ene	ects of imatinib.				
45 0110 1507 750110							
15. SUBJECT TERMS Chronic myelogene		enetics, DNA methy	rlation, decitabine, ir	natinib, clinica	l trial		
, 0	. , 3	,	,	·			
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON		
a. REPORT	b. ABSTRACT	c. THIS PAGE	- ABOTINAOT	JI I AGEG	USAMRMC  19b. TELEPHONE NUMBER (include area		
U	U	U	UU	8	code)		

UU

8

## **Table of Contents**

Introduction	4-5
Body	5-8
Key Research Accomplishments	4-5
Reportable Outcomes	5
Conclusions	4-8
References	5
List of personnel	4
Appendices	none

## FINAL ADDENDUM REPORT USAMRMC FY02 CHRONIC MYELOGENOUS LEUKEMIA RESEARCH PROGRAM

Grant/Contract/MIPR No.: DAMD17-03-1-0448

**Principal Investigator:** <u>Jean-Pierre Issa</u>, M.D.

**Institution:** University of Texas M.D. Anderson Cancer

Center

Houston, Texas

**Report Title:** Epigenetic Silencing and Resistance to

Imatinib Mesylate in CML

**Report Type:** Final Addendum

**Award Mechanism:** Investigator-Initiated Research

**Date of Report:** August 2007

**Reporting Period:** July 1, 2006 – July 1, 2007

We performed analyses of DNA methylation data reported in the final report with clinical outcome of CML patients. DNA methylation significantly correlated with survival. CML patients with average methylation z-score values above zero had significantly shorter survival than patients with z-scores below zero (median 10 months vs 59 months, P<0.0001). This was true also within CP (median survival of 44 months for patients with high methylation vs median not reached in patients with low methylation, P=0.02) and AP (median survival of 11 months for patients with high methylation vs 27 months in patients with low methylation, P=0.009). Changes in gene silencing by DNA methylation may play a role in developing alternative routes for cells to circumvent the effects of imatinib.

We expanded our analysis in CML patients to HOX developmental genes. The HOX gene family consists of 39 genes organized in 4 clusters A-D on 4 chromosomes in 13 paralogous groups. These genes regulate developmental processes and tissue differentiation. HOX gene translocations are frequently found in leukemia. Most HOX genes have CpG islands at their TSS. Silencing of HOX genes by DNA methylation may disrupt normal development of blood cells and thus be involved in leukemic transformation. We performed comprehensive DNA methylation analyses of 31 HOX genes with CpG islands in transcription start site (TSS) regions (HOXA1, 4, 5, 6, 7, 9, 10a, 10b, 11 and 13; HOXB1, 4, 5, 7, 8, 9, and 13; HOXC4, 5, 8, 9, 10, 11, and 13; HOXD1, 4, 8, 9, 10, 11, and 13). We analyzed DNA in blood cells from 20 CML

patients, comparing the results with 25 normal controls. We used bisulfite pyrosequencing to quantitate levels of cytosine methylation in CpG islands at TSS. Statistical analyses were performed with nonparametric tests. Asterisks (\*) denote statistically significant methylation differences from normal controls (p<0.05). HOXA5 and HOXB1 genes showed dense methylation both in normal controls and in primary leukemic cells. HOXA4, A6 and HOXC4 genes showed moderately elevated methylation in normal controls (medians 13%, 15%, and 34%) and increased methylation in CML (87%\*, 32%\* and 28%). The remaining HOX genes were not methylated in normal controls. HOXB8 and B13 showed increased median methylation levels in CML (14% and 17%\*). HOXC11 and C13 median methylation levels were also increased in CML (25%\* and 13%). HOXD4 and D11 genes also showed a tendency to increased methylation in some CML patients (medians 17% and 25%).

## **Reportable outcomes**

Poster presentation at the Annual Meetings of the American Society of Hematology 2006

Jelinek J, Gharibyan V, Oki Y, Chung W, Shen L, Cortes JE, Kantarjian HM, Issa JPJ. Aberrant DNA Methylation in CML Is Associated with Disease Progression and Resistance to Imatinib Mesylate. Blood 2006; 108: 622a

Poster presentation at Annual Meeting of the American Association for Cancer Research 2007

DNA methylation of HOX genes in leukemia and myeloproliferative disorders. American Association for Cancer Research Annual Meeting, Los Angeles, CA, April 14-18, 2007.

Oral presentation at the "Road to a Cure: the Chronic Myelogenous Research Program Investigators Meeting" Orlando, FL, December 7-8, 2006

DNA methylation in CML increases with disease progression, and associates with resistance to imatinib mesylate and shortened survival.

Figure 1. Increased DNA methylation average z-score is associated with shorter survival in CML patients. Low methylation, average z-score below 0; high methylation, average z-score above 0. CP, chronic phase; AP, accelerated phase; BC, blast crisis.




Figure 2. Methylation of HOX genes in CML patients and normal controls.

